Why can't I see BoomRx pricing before I commit?

The pricing transparency problem shows up at the worst moment: a patient is in front of you ready to start semaglutide or tirzepatide, and you cannot tell them the cost because your platform does not show landed per-vial pricing yet. You either guess, quote a padded number to be safe, or tell the patient you will follow up — and follow-ups are where conversions go to die.

For owners, the same opacity makes margin planning a moving target. BoomRx markets competitive pricing and a $30 flat cold-chain shipping fee, but if the cost per vial is only knowable after signup and inside the portal, building a predictable cash-pay program means working from averages rather than line-item numbers. The delay is not just minutes; it is the inability to make confident pricing decisions before you are live.

BoomRx advertises competitive pricing guaranteed and reports average 20% lower cost versus industry on boomrx.com, but per-SKU rates are not published publicly as of June 2026. Clinics reach the team through an inquiry form, complete provider signup, and then see pricing inside the dashboard. That is a deliberate model for a sales-led platform: rates are set through the hub relationship rather than on a public price list. It can yield good pricing at volume, but the trade-off is that you do not see a number until you are onboarded.

When you evaluate this model, the right questions are about timing and visibility: how long from inquiry to dashboard access, whether per-vial rates appear on every SKU you order, and how the $30 flat shipping fee affects landed cost on your top GLP-1 lines. If pricing never surfaces in a way you can use during the consult, the signup gate repeats every time you evaluate a new formulary addition.

The delay disappears when pricing is visible at the point of decision. Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with the facilitation fee disclosed at payment, so a clinician can quote a patient in the room and an owner can model margin from real numbers. There is no inquiry gate between you and the cost of the medication you are about to order.

Pass-through pricing is the structural difference: instead of a dashboard rate revealed after signup, you see the 503A cost and the disclosed fee. The evaluation test is whether you can answer what does this vial cost without waiting on onboarding. When the catalog answers that question, the consult keeps moving and pricing stops being a bottleneck.